




*elected paper*

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2002:97692 CAPLUS Full-text  
DN 137:103383  
TI Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel  
potent and selective  $\alpha V\beta 3$  antagonists  
AU Kling, Andreas; Backfisch, Gisela; Delzer, Jurgen; Geneste, Herve;  
Graef, Claudia; Holzenkamp, Uta; Hornberger, Wilfried; Lange, Udo E. W.;  
Lauterbach, Arnulf; Mack, Helmut; Seitz, Werner; Subkowski, Thomas  
CS Knoll GmbH, Ludwigshafen, D-67008, Germany  
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(3), 441-446  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 137:103383  
GI



AB Substituted oxodibenzazepineacetic acids substituted with guanidines or  
guanidine pharmacophores such as I are prepared as potential  $\alpha V\beta 3$   
(vitronectin receptor) antagonists. The oxodibenzazepineacetic acid  
core II is prepared in 5 steps from 9,10-anthraquinone; coupling of II  
with guanidine or guanidine pharmacophore-substituted amines such as III  
followed by hydrolysis of the Me ester yields compds. such as I.  
Structure-activity relationships are determined for the guanidine or  
guanidine pharmacophore-substituted oxodibenzazepineacetic acids,  
varying the linker between the guanidine pharmacophore and the  
oxodibenzazepine and the choice of guanidine pharmacophore. Compound I  
and a second guanidine pharmacophore-substituted oxodibenzazepineacetic  
acid are found to be highly active inhibitors of the vitronectin  
receptor in vitro and are found to be bioavailable in ADME assays.


IT 326400-55-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)  
(preparation of guanidine or guanidine pharmacophore-substituted  
oxodibenzazepineacetic acids as potential  $\alpha V\beta 3$  receptor  
antagonists)


RN 326400-55-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 326400-60-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
RACT (Reactant or reagent) (preparation of guanidine or guanidine  
pharmacophore-substituted oxodibenzazepineacetic acids as potential  $\alpha\text{v}\beta 3$   
receptor antagonists)

RN 326400-60-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






RE.CNT 50      THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:115130 CAPLUS Full-text  
 DN 134:178474  
 TI Preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists  
 IN Kling, Andreas; Geneste, Herve; Lange, Udo; Lauterbach, Arnulf; Graef, Claudia Isabella; Subkowski, Thomas; Holzenkamp, Uta; Mack, Helmut; Sadowski, Jens; Hornberger, Wilfried; Laux, Volker  
 PA BASF Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 158 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010847	A2	20010215	WO 2000-EP7440	20000801
	WO 2001010847	A3	20011101		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19936780	A1	20010215	DE 1999-19936780	19990809
	CA 2379977	AA	20010215	CA 2000-2379977	20000801
	EP 1202988	A2	20020508	EP 2000-958347	20000801
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000013265	A	20020514	BR 2000-13265	20000801
	TR 200200357	T2	20020923	TR 2002-200200357	20000801
	JP 2003506441	T2	20030218	JP 2001-515313	20000801
	BG 106395	A	20021229	BG 2002-106395	20020206
	NO 2002000644	A	20020318	NO 2002-644	20020208
PRAI	DE 1999-19936780	A	19990809		
	WO 2000-EP7440	W	20000801		
OS	MARPAT 134:178474				
GI					




AB RZZ1R1 [I; R = group contg,  $\geq 1$  non-H H-bonding atom; R1 = CO<sub>2</sub>H, or group hydrolyzable to CO<sub>2</sub>H; Z = e.g., (hetero)annelated 2-oxo-1-benzazepin-1,5-diyl; Z1 = bond, (un)substituted NHCH<sub>2</sub>, -OCH<sub>2</sub>, -alkylene, -CH:CH, etc.] were prepared Thus, Me 11-methoxycarbonylmethyl-6-oxo-6,11-dihydro-5H-dibenz[b,e]azepine-5-acetate (preparation given) was amidated by N-(2-aminoethyl)pyridine-2-amine to give, after saponification, title compound II. Data for biol. activity of I were given.

IT 326400-55-9P 326400-60-6P


RL: BAC (Biological activity or effector, except adverse); BSU  
(Biological study, unclassified); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses) (preparation of oxobenzazepinealkanoates and analogs as integrin  
receptor antagonists)

RN 326400-55-9 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-  
ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA  
INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-60-6 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-  
ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl  
ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



=> d l1; d his; log y  
L1 HAS NO ANSWERS  
L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

(FILE 'STNGUIDE' ENTERED AT 16:13:51 ON 06 JAN 2005)  
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 16:14:47 ON 06 JAN 2005  
L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 2 S L1 FUL




FILE 'CAPLUS' ENTERED AT 16:15:19 ON 06 JAN 2005  
L4 2 S L3

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	10.33	333.32
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

STN INTERNATIONAL LOGOFF AT 16:15:54 ON 06 JAN 2005

Compound made by Byz

L11 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2002:97692 CAPLUS Full-text  
DN 137:103383  
TI Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel  
potent and selective  $\alpha\text{V}\beta 3$  antagonists  
AU Kling, Andreas; Backfisch, Gisela; Delzer, Jurgen; Geneste, Herve;  
Graef, Claudia; Holzenkamp, Uta; Hornberger, Wilfried; Lange, Udo E. W.;  
Lauterbach, Arnulf; Mack, Helmut; Seitz, Werner; Subkowski, Thomas  
CS Knoll GmbH, Ludwigshafen, D-67008, Germany  
SO Bioorganic & Medicinal Chemistry Letters (2002), 12(3), 441-446  
CODEN: BMCLE8; ISSN: 0960-894X  
PB Elsevier Science Ltd.  
DT Journal  
LA English  
OS CASREACT 137:103383  
GI



AB Substituted oxodibenzazepineacetic acids substituted with guanidines or  
guanidine pharmacophores such as I are prepared as potential  $\alpha\text{V}\beta 3$   
(vitronectin receptor) antagonists. The oxodibenzazepineacetic acid  
core II is prepared in 5 steps from 9,10-anthraquinone; coupling of II  
with guanidine or guanidine pharmacophore-substituted amines such as III  
followed by hydrolysis of the Me ester yields compds. such as I.  
Structure-activity relationships are determined for the guanidine or  
guanidine pharmacophore-substituted oxodibenzazepineacetic acids,  
varying the linker between the guanidine pharmacophore and the  
oxodibenzazepine and the choice of guanidine pharmacophore. Compound I  
and a second guanidine pharmacophore-substituted oxodibenzazepineacetic  
acid are found to be highly active inhibitors of the vitronectin  
receptor in vitro and are found to be bioavailable in ADME assays.

IT 326401-69-8P 326401-92-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)

(preparation of a guanidine or guanidine pharmacophore-substituted  
oxodibenzazepineacetic acid and lack of activity as a potential  
 $\alpha\text{V}\beta 3$  receptor antagonist)

RN 326401-69-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-


[[[4-

[(1-oxo-3-phenylpropyl)amino]phenyl]methyl]amino]ethyl]- (9CI) (CA




INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326401-92-7 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-[[4-  
[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methoxy]ethyl]- (9CI) (CA  
INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 326398-90-7P 326399-52-4P 326399-69-3P

326399-78-4P 326399-83-1P 326400-55-9P  
 326400-65-1P 326400-70-8P 326401-04-1P  
 326401-08-5P 326401-18-7P 326401-26-7P  
 326401-36-9P 326401-41-6P 326401-74-5P  
 326401-97-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (preparation of guanidine or guanidine pharmacophore-substituted  
 oxodibenzazepineacetic acids as potential  $\alpha\text{V}\beta\text{3}$  receptor  
 antagonists)

RN 326398-90-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-  
 3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
 NAME)


PAGE 1-A



PAGE 2-A




RN 326399-52-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-yl)-  
 2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
 NAME)




RN 326399-69-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[4-(1H-imidazo[4,5-b]pyridin-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326399-78-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326399-83-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-yl)phenyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-55-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326400-65-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326400-70-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-


ylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326401-04-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[4-(1H-benzimidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-08-5 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[4-  
 [(2-pyridinylamino)methyl]-2-thienyl)methyl]amino]ethyl]- (9CI) (CA  
 INDEX  
 NAME)

PAGE 1-A




PAGE 2-A




RN 326401-18-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[4-  
 (2-pyridinylamino)phenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 326401-26-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-

[[[4-


[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI)  
(CA INDEX NAME)



PAGE 1-A



PAGE 2-A



RN 326401-36-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5-chloro-1H-benzimidazol-

2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA


INDEX

NAME)

PAGE 1-A




PAGE 2-A




RN 326401-41-6 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5,6-dimethyl-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-74-5 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[[ (phenylmethoxy) carbonyl] amino] phenyl] methyl] amino] ethyl]- (9CI) (CA  
INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 326401-97-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[4-[4-  
[[[ (phenylmethyl) amino] carbonyl] amino] phenyl] butyl]- (9CI) (CA INDEX  
NAME)




IT 90664-75-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of guanidine or guanidine pharmacophore-substituted  
oxodibenzazepineacetic acids as potential  $\alpha\text{V}\beta\text{3}$  receptor  
antagonists)

RN 90664-75-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-, methyl ester  
(9CI) (CA INDEX NAME)



IT 90664-74-7P 326400-60-6P 326401-22-3P

326404-40-4P 326404-44-8P 326404-49-3P

326408-08-6P 326408-33-7P 326410-52-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(preparation of guanidine or guanidine pharmacophore-substituted  
oxodibenzazepineacetic acids as potential  $\alpha\text{V}\beta\text{3}$  receptor  
antagonists)


RN 90664-74-7 CAPLUS

CN Acetic acid, (5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)-,  
methyl  
ester (9CI) (CA INDEX NAME)




RN 326400-60-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-22-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-

[[[4-  
 [[[phenylmethyl]amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-,  
 methyl  
 ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 326404-40-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-5-acetic acid, 6,11-dihydro-11-(2-methoxy-2-oxoethylidene)-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 326404-44-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-5,11-diacetic acid, 6,11-dihydro-6-oxo-,  
 α5-(1,1-dimethylethyl) α11-methyl ester (9CI) (CA INDEX NAME)




RN 326404-49-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-5,11-diacetic acid, 6,11-dihydro-6-oxo-,  
 α11-methyl ester (9CI) (CA INDEX NAME)




RN 326408-08-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-  
 3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 326408-33-7 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
(9CI)  
(CA INDEX NAME)






RE.CNT 50      THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:115130 CAPLUS Full-text  
 DN 134:178474  
 TI Preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists  
 IN Kling, Andreas; Geneste, Herve; Lange, Udo; Lauterbach, Arnulf; Graef, Claudia Isabella; Subkowski, Thomas; Holzenkamp, Uta; Mack, Helmut; Sadowski, Jens; Hornberger, Wilfried; Laux, Volker  
 PA BASF Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 158 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010847	A2	20010215	WO 2000-EP7440	20000801
	WO 2001010847	A3	20011101		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 19936780	A1	20010215	DE 1999-19936780	19990809
	CA 2379977	AA	20010215	CA 2000-2379977	20000801
	EP 1202988	A2	20020508	EP 2000-958347	20000801
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	BR 2000013265	A	20020514	BR 2000-13265	20000801
	TR 200200357	T2	20020923	TR 2002-200200357	20000801
	JP 2003506441	T2	20030218	JP 2001-515313	20000801
	BG 106395	A	20021229	BG 2002-106395	20020206
	NO 2002000644	A	20020318	NO 2002-644	20020208
PRAI	DE 1999-19936780	A	19990809		
	WO 2000-EP7440	W	20000801		
OS	MARPAT 134:178474				
GI					



AB RZZ1R1 [I; R = group contg,  $\geq 1$  non-H H-bonding atom; R1 = CO<sub>2</sub>H, or group hydrolyzable to CO<sub>2</sub>H; Z = e.g., (hetero)annelated 2-oxo-1-benzazepin-1,5-diyl; Z1 = bond, (un)substituted NHCH<sub>2</sub>, -OCH<sub>2</sub>, -alkylene, -CH:CH, etc.] were prepared. Thus, Me 11-methoxycarbonylmethyl-6-oxo-6,11-dihydro-5H-dibenz[b,e]azepine-5-acetate (preparation given) was amidated by N-(2-aminoethyl)pyridine-2-amine to give, after saponification, title compound II. Data for biol. activity of I were given.

IT 326398-79-2P 326398-84-9P 326398-90-7P  
326399-01-3P 326399-07-9P 326399-11-5P  
326399-17-1P 326399-23-9P 326399-27-3P  
326399-31-9P 326399-36-4P 326399-42-2P  
326399-47-7P 326399-52-4P 326399-64-8P  
326399-69-3P 326399-73-9P 326399-78-4P  
326399-83-1P 326400-13-9P 326400-18-4P  
326400-23-1P 326400-28-6P 326400-32-2P  
326400-41-3P 326400-45-7P 326400-50-4P  
326400-55-9P 326400-60-6P 326400-65-1P  
326400-70-8P 326400-74-2P 326400-79-7P  
326400-84-4P 326400-88-8P 326400-94-6P  
326400-99-1P 326401-04-1P 326401-08-5P  
326401-13-2P 326401-18-7P 326401-22-3P  
326401-26-7P 326401-32-5P 326401-36-9P  
326401-41-6P 326401-46-1P 326401-50-7P  
326401-54-1P 326401-59-6P 326401-64-3P  
326401-69-8P 326401-74-5P 326401-82-5P  
326401-87-0P 326401-92-7P 326401-97-2P  
326402-02-2P 326402-06-6P 326402-11-3P  
326402-16-8P 326402-21-5P 326402-26-0P  
326402-31-7P 326402-35-1P 326402-40-8P  
326402-44-2P 326402-48-6P 326402-52-2P  
326402-57-7P 326402-62-4P 326402-66-8P  
326402-71-5P 326402-76-0P 326402-80-6P  
326402-85-1P 326402-90-8P 326402-94-2P  
326402-99-7P 326403-04-7P 326403-08-1P  
326403-13-8P 326403-18-3P 326403-22-9P  
326403-28-5P 326403-32-1P 326403-37-6P  
326403-42-3P 326403-47-8P 326403-51-4P  
326403-56-9P 326403-61-6P 326403-66-1P  
326403-71-8P 326403-76-3P 326404-18-6P  
326404-23-3P 326404-27-7P 326404-31-3P  
326404-36-8P 326471-39-0P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);


BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists)


RN 326398-79-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(2-pyridinylamino)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 326398-84-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326398-90-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326399-01-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[(4,5-dihydro-1H-imidazol-2-yl)amino]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326399-07-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(4,5-dihydro-1H-imidazol-2-yl)-3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate

CRN 326399-06-8  
CMF C27 H25 N5 O4


PAGE 1-A



PAGE 2-A




CRN 64-19-7  
CMF C2 H4 O2




RN 326399-11-5 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[1-(2-pyridinyl)-4-piperidinyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 326399-17-1 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 326399-16-0  
CMF C26 H22 N4 O4



CM 2

CRN 64-19-7

CMF C2 H4 O2



RN 326399-23-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[(1H-imidazo[4,5-

b]pyridin-2-ylmethyl)amino]-2-oxoethyl]-6-oxo-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 326399-22-8

CMF C25 H21 N5 O4




CM 2

CRN 64-19-7




CMF C2 H4 O2




RN 326399-27-3 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-[[2-(2-pyridinylamino)ethyl]amino]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326399-31-9 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-[4-(2-pyridinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 326399-36-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[3-[[[4-(1H-benzimidazol-2-yl)-  
 2-thienyl]methyl]amino]-3-oxopropyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
 NAME)




RN 326399-42-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinylamino)methyl]-1-piperidinyl]ethyl]-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 326399-41-1  
CMF C29 H30 N4 O4

PAGE 1-A




PAGE 2-A




CM 2

CRN 64-19-7  
CMF C2 H4 O2




RN 326399-47-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
[(phenylmethyl)amino]carbonyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX  
NAME)



RN 326399-52-4 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-yl)-  
2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
NAME)



RN 326399-64-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
 2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI)  
 (CA INDEX NAME)


CM 1

CRN 326399-63-7  
 CMF C30 H24 N4 O4 S




CM 2

CRN 64-19-7  
 CMF C2 H4 O2




RN 326399-69-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[4-(1H-imidazo[4,5-b]pyridin-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo-  
 (9CI) (CA INDEX NAME)




RN 326399-73-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monohydrochloride  
(9CI) (CA INDEX NAME)

PAGE 1-A






RN 326399-78-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
 2-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
 NAME)




RN 326399-83-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-  
 yl)phenyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-13-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(1H-imidazol-2-ylamino)-3-oxopropyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A








RN 326400-18-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[[[(phenylmethyl)amino]carbonyl]amino]methyl]-1-piperidinyl]ethyl]- (9CI)

(CA INDEX NAME)




RN 326400-23-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-[[[1-(2-pyridinyl)-4-piperidinyl]methyl]amino]propyl]- (9CI)

(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-28-6 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-  
[[[1-  
[[ (phenylmethyl)amino]carbonyl]-4-piperidinyl]methyl]amino]propyl]-  
(9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-32-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[3-[[[5-(1H-benzimidazol-2-yl)-  
2-  
thienyl]methyl]amino]-3-oxopropyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326400-41-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[1-  
 [[(phenylmethyl)amino]carbonyl]-4-piperidinyl]methyl]amino]ethyl]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A





PAGE 2-A




RN 326400-45-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-

[[[(phenylmethyl)amino]carbonyl]amino]methyl]phenyl]methyl]amino]ethyl]-  
(9CI) (CA INDEX NAME)




RN 326400-50-4 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinylamino)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326400-55-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-60-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 326400-65-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326400-70-8 CAPLUS




CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-ylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326400-74-2 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[3-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326400-79-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[(1H-benzimidazol-2-ylamino)methyl]-1-piperidiny]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-84-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[2-(2-pyridinylamino)-4-thiazolyl]methyl]amino]ethyl]- (9CI) (CA INDEX  
NAME)

PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 326400-88-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[2-  
(2-pyridinylamino)-5-thiazolyl]methyl]amino]ethyl]- (9CI) (CA INDEX  
NAME)

PAGE 1-A



PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 326400-94-6 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[2-[(aminoiminomethyl)amino]-

4-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 326400-93-5


CMF C23 H22 N6 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 326400-99-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[2-[(aminoiminomethyl)amino]-

5-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA


INDEX

NAME)




RN 326401-04-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[4-(1H-benzimidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-08-5 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[(2-pyridinylamino)methyl]-2-thienyl)methyl]amino]ethyl]- (9CI) (CA  
INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326401-13-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[methyl[2-(2-  
pyridinylamino)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326401-18-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-(2-pyridinylamino)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 326401-22-3 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-,  
methyl  
ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A





RN 326401-26-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-


[[[4-

[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI)  
(CA INDEX NAME)




RN 326401-32-5 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-  
6- [(aminoiminomethyl)amino]phenyl)methyl]amino]-2-oxoethyl]-6,11-dihydro-  
oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
CM 1  
CRN 326401-31-4  
CMF C26 H25 N5 O4

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 326401-36-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5-chloro-1H-benzimidazol-

2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA


INDEX

NAME)

PAGE 1-A





PAGE 2-A




RN 326401-41-6 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5,6-dimethyl-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A






RN 326401-46-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[3-(2-pyridinylamino)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326401-50-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinylamino)ethyl]-1-piperidinyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-54-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
[2-  
(2-pyridinylamino)ethyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-59-6 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[3-  
[2-  
(2-pyridinylamino)ethyl]-1-pyrrolidinyl]ethyl]-, methyl ester (9CI) (CA  
INDEX NAME)



PAGE 1-A





PAGE 2-A



RN 326401-64-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[3-  
[2-  
(2-pyridinylamino)ethyl]-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 326401-69-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-

INDEX  
NAME)


INDEX

NAME )

PAGE 1-A



PAGE 2-A





RN 326401-74-5 CAPIUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-

[[[4-

[[ (phenylmethoxy) carbonyl] amino] phenyl] methyl] amino] ethyl] - (9CI) (CA  
INDEX NAME)




RN 326401-82-5 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[5-  
 [[[ (phenylmethyl) amino] carbonyl] amino] pentyl]- (9CI) (CA INDEX NAME)



RN 326401-87-0 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[(4-  
 aminophenyl)methoxy]ethyl]-  
 6,11-dihydro-6-oxo-, methyl ester, monohydrochloride (9CI) (CA INDEX  
 NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 326401-92-7 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-[[4-  
[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methoxy]ethyl]- (9CI) (CA  
INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 326401-97-2 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[4-[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]butyl]- (9CI) (CA INDEX NAME)




RN 326402-02-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-acetic acid, 11-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-,


monohydrochloride (9CI) (CA INDEX NAME)



RN 326402-06-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(4-methyl-  
 1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-11-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(4-methyl-1-  
 piperazinyl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 326402-16-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(3-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 326402-21-5 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)






RN 326402-26-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[1-methyl-2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-31-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[1-ethyl-2-pyrrolidinyl)methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326402-35-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(4-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


CH<sub>2</sub>-CO<sub>2</sub>H

RN 326402-40-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-


[2-

(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326402-44-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(diethylamino)ethyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-48-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326402-52-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-57-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(2-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-62-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-66-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[3-(dibutylamino)propyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-71-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 326402-76-0 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[4-[3-(4-morpholinyl)propyl]-1-piperazinyl]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

CH<sub>2</sub>-CO<sub>2</sub>H

RN 326402-80-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(2-methyl-  
 1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-85-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(4-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-90-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[(1-methyl-4-piperidinyl)amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)






RN 326402-94-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(2-  
 (1-  
 piperidinyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-99-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
 [3-  
 (1-pyrrolidinyl)propyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326403-04-7 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(dimethylamino)ethyl]-  
1-  
piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-08-1 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[3-(dimethylamino)propyl]-

1-  
 piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-13-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(dipropylamino)ethyl]-  
 1-  
 piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-18-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
 [2-  
 (1-piperidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326403-22-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[3-(dipropylamino)propyl]-  
 1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-28-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(dibutylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-32-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




PAGE 1-A




RN 326403-37-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[3-(diethylamino)propyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME).




RN 326403-42-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-47-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(dimethylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-51-4 CAPLUS  
 CN Propanoic acid, 3-[5,6-dihydro-6-oxo-5-[2-oxo-2-[[[4-  
 [[[phenylmethyl]amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-11H-  
 dibenz[b,e]azepin-11-ylidene]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326403-56-9 CAPLUS  
 CN Propanoic acid, 3-[5,6-dihydro-6-oxo-5-[2-oxo-2-[[[4-  
 [[[phenylmethyl]amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-11H-  
 dibenz[b,e]azepin-11-ylidene]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326403-61-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-,  
 methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 326403-66-1 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326403-71-8 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[2-  
(2-pyridinylamino)ethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326403-76-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[2-(2-pyridinylamino)ethyl]amino]ethyl]-, monosodium salt (9CI) (CA INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326404-18-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[[[4-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]carbonyl]-2-thiazolyl]methyl]-6,11-dihydro-6-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326404-23-3 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[4-[(2-pyridinylamino)methyl]-1-piperidinyl]carbonyl]-2-thiazolyl]methyl]-  
(9CI)

(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326404-27-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]carbonyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326404-31-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-  
[(2-  
pyridinylamino)methyl]phenyl)methyl]amino]carbonyl]-2-thiazolyl)methyl]-  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326404-36-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-(2-pyridinylamino)methyl]-2-thienyl)methyl]amino]carbonyl]-2-thiazolyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326471-39-0 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI)  
(CA INDEX NAME)

CM 1

CRN 326471-38-9  
CMF C24 H22 N4 O4 S






CM 2

CRN 64-19-7

CMF C2 H4 O2




IT 90664-74-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of oxobenzazepinealkanoates and analogs as integrin  
receptor antagonists)

RN 90664-74-7 CAPLUS

CN Acetic acid, (5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)-,  
methyl ester (9CI) (CA INDEX NAME)



IT 21607-74-9P 90664-75-8P 326404-40-4P  
326404-44-8P 326404-49-3P 326404-53-9P  
326404-66-4P 326404-70-0P 326407-41-4P  
326407-57-2P 326407-61-8P 326407-89-0P  
326407-94-7P 326407-99-2P 326408-04-2P  
326408-08-6P 326408-13-3P 326408-23-5P  
326408-28-0P 326408-33-7P 326408-41-7P  
326408-46-2P 326408-54-2P 326408-59-7P  
326408-63-3P 326408-68-8P 326409-96-5P  
326410-02-0P 326410-07-5P 326410-52-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of oxobenzazepinealkanoates and analogs as integrin


receptor

antagonists)


RN 21607-74-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo- (9CI) (CA  
 INDEX  
 NAME)




RN 90664-75-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)




RN 326404-40-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-5-acetic acid, 6,11-dihydro-11-(2-methoxy-2-  
 oxoethylidene)-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 326404-44-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-5,11-diacetic acid, 6,11-dihydro-6-oxo-,  
 α5-(1,1-dimethylethyl) α11-methyl ester (9CI) (CA INDEX NAME)




RN 326404-49-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-5,11-diacetic acid, 6,11-dihydro-6-oxo-,  
 α11-methyl ester (9CI) (CA INDEX NAME)



RN 326404-53-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-,  
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 326404-66-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-5-propanoic acid, 11-[2-(1,1-dimethylethoxy)-2-  
 oxoethyl]-6,11-dihydro-6-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 326404-70-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-propanoic acid, 11-[2-(1,1-dimethylethoxy)-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326407-41-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-5,11-diacetic acid, 6,11-dihydro-6-oxo-, alpha11-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 326407-57-2 CAPLUS


CN 5H-Dibenz[b,e]azepine-5-acetic acid, 6,11-dihydro-11-(3-methoxy-3-oxopropylidene)-6-oxo- (9CI) (CA INDEX NAME)




RN 326407-61-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 5-(carboxymethyl)-6,11-dihydro-  
 6-  
 oxo-,  $\alpha$ -methyl ester (9CI) (CA INDEX NAME)



RN 326407-89-0 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[(4-carboxy-2-thiazolyl)methyl]-  
 6,11-dihydro-6-oxo-,  $\alpha$ -(1,1-dimethylethyl) ester (9CI) (CA INDEX  
 NAME)




RN 326407-94-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[[4-(ethoxycarbonyl)-2-  
 thiazolyl]methyl]-6,11-dihydro-6-oxo-, 1,1-dimethylethyl ester (9CI)  
 (CA  
 INDEX NAME)




RN 326407-99-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(2-pyridinylamino)ethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 326408-04-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 326408-08-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




PAGE 1-A



RN 326408-13-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 326408-23-5 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(aminothioxomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)  
(CA INDEX NAME)



PAGE 1-A





PAGE 2-A



RN 326408-28-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
(9CI)

(CA INDEX NAME)




RN 326408-33-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
2-  
thienyl)methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
(9CI)

(9CI)


(CA INDEX NAME)




RN 326408-41-7 CAPLUS



CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(1H-imidazol-2-ylamino)-3-oxopropyl]amino]-2-oxoethyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






RN 326408-46-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[5-[(hydroxyamino)iminomethyl]-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 326408-54-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[5-[[[(phenylmethyl)amino]carbonyl]amino]pentyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 326408-59-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[(4-nitrophenyl)methoxy]ethyl]-6-oxo-, methyl ester, monohydrochloride (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 326408-63-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[4-(4-nitrophenyl)butyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326408-68-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-5-acetic acid, 11-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 326409-96-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-(cyanomethyl)-6,11-dihydro-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 326410-02-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-(1-piperazinyl)ethyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA


INDEX

NAME)

CM 1

CRN 326410-01-9


CMF C23 H25 N3 O4



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 326410-07-5 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
[[ (phenylmethyl)amino]carbonyl]-1-piperazinyl]ethyl]-, methyl ester  
(9CI)

(CA INDEX NAME)



RN 326410-52-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-(2-hydroxyethyl)-6-  
oxo-, methyl ester (9CI) (CA INDEX NAME)





L11 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1984:438368 CAPLUS Full-text

DN 101:38368

TI 5,6-Dihydro-11-H-morphanthridin-6-ones and drugs containing them

IN Steiner, Gerd; Friedrich, Ludwig; Lenke, Dieter

PA BASF A.-G. , Fed. Rep. Ger.

SO Ger. Offen., 18 pp.

CODEN: GWXXBX


DT Patent

LA German


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3326641	A1	19840202	DE 1983-3326641	19830723
PRAI	DE 1982-3227934	A1	19820727		

GI



I



II


AB Morphanthridinones I [R1, R2 = H, halo, C1-3 alkyl, CF3; R3 = 1-piperazinyl with N4-(un)substituted by C1-3 alkyl, C2-3 hydroxyalkyl, or F-, Cl-, MeO-, or Me-(un)substituted Ph; R3 = C2-4 aminoalkyl, (methyl)morpholinoalkyl] and their physiol. tolerable acid addition salts, useful in treating illnesses accompanied by patholog. increased stomach secretion, e.g., stomach and duodenal ulcers (no data), were prepared Thus, hydrogenating 11-(carbomethoxymethylene)-5,6-dihydromorphanthridin-6-one over 10% Pd/C in MeOH gave 94% 11-(carbomethoxymethyl) analog, which was saponified in refluxing aqueous ethanolic NaOH to give 96% cis,trans-11- (carboxymethyl) analog. This was converted with SOCl2 into 99% acid chloride, which reacted with 1-methylpiperazine to give 80% amide II.

IT **90664-74-7**

RL: RCT (Reactant); RACT (Reactant or reagent) (hydrogenation of)

RN 90664-74-7 CAPLUS

CN Acetic acid, (5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)-, methyl ester (9CI) (CA INDEX NAME)




IT **21607-74-9P**

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and conversion into acid chloride)

RN 21607-74-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




IT **90664-75-8P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent) (preparation and saponification of)


RN 90664-75-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)



L11 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1976:180092 CAPLUS Full-text  
 DN 84:180092  
 TI Sulfonylureas and sulfonyl semicarbazides with antidiabetic action  
 IN Winter, Werner; Fauland, Erich; Stach, Kurt; Schmidt, Felix Helmut;  
 AumueUeller, Walter  
 PA Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.  
 SO Ger., 8 pp.  
 CODEN: GWXXAW  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1618112	A	19720510	DE 1967-B91627	19670315
	DE 1618112	B2	19750612		
	DE 1618112	C3	19760212		
	US 3646009	A	19720229	US 1968-711840	19680311
	GB 1153130	A	19690521	GB 1968-1153130	19680313
	CH 516535	A	19711215	CH 1968-516535	19680313
	CH 516541	A	19711215	CH 1968-516541	19680313
	CH 516542	A	19711215	CH 1968-516542	19680313
	NL 6803656	A	19680916	NL 1968-3656	19680314
	AT 281052	B	19700525	AT 1968-2545	19680314
	AT 281061	B	19700525	AT 1969-5843	19680314
	AT 281062	B	19700525	AT 1969-5844	19680314
	AT 281063	B	19700525	AT 1969-5845	19680314
	FR 1556173	A	19690131	FR 1968-1556173	19680315
	US 3752851	A	19730814	US 1971-182516	19710921
PRAI	DE 1967-B91627	A	19670315		
	US 1968-711840	A3	19680311		
GI					




AB Sulfonylureas I (X=CH<sub>2</sub>CH<sub>2</sub>, CH:CH, OCH<sub>2</sub>, SCH<sub>2</sub>, O, S, bond; X<sub>1</sub>=:CH, :CHCH<sub>2</sub>, :C:CH; R = cycloalkyl, hexamethylenimino, substituted piperidino, tetrahydrothiopyranyl) (34 compds.) were prepared e.g. by treating the carbamates with RNH<sub>2</sub>. I had 12-16,000 times the antidiabetic activity of 4-H<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NHCONHBu.

IT **21607-74-9P**

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 21607-74-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



L11 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1969:96656 CAPLUS Full-text

DN 70:96656

TI Oxepin and thiepin derivatives of acetamide

IN Winter, Werner; Thiel, Max; Stach, Kurt; Schaumann, Wolfgang;  
Ribbentrop,

Annemarie

PA Boehringer, C. F., und Soehne G.m.b.H.

SO S. African, 18 pp.

CODEN: SFXXAB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	ZA 6707555		19680425		
	DE 1568217			DE	
	FR 1547207			FR	
	GB 1144829			GB	

PRAI DE 19661216

AB A mixture of 25.4 g. 6,11-dihydrodibenz[b,e]oxepin-11-ylideneacetic acid, m. 114-15°, and 40 ml. SOCl<sub>2</sub> was refluxed 2 hrs., evaporated, the residue in Et<sub>2</sub>O mixed with 50 ml. NH<sub>3</sub>, and the mixture kept overnight and worked up to give 79% 11-carboxamidomethylene-6,11-dihydrodibenz[b,e]oxepin (I), m. 205° (iso-PrOH). Analogously prepared were 82% 5-carboxamidomethyl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene (II), m. 137-8°; 5-carboxamidomethylene-5H-dibenzo[a,d]cycloheptene (III), m. 144-5°; 81% 5-carboxamidomethyl analog of III, m. 207-8°; 80% theipin analog of I, m. 209-10°; 78% 11-carboxamidomethyl-6,11-dihydrodibenzo[b,e]thiepin, m. 194-5°; 72% 12-carboxamidomethylene-7,12-dihydro-6H-dibenzo[b,e]-thiocin, m. 171-3°; 78% 11-carboxamidomethylene-2-methyl-6,11-dihydrodibenz[b,e]oxepin, m. 202°; 11-carboxamidomethyl-2-methyl-6,11-dihydrodibenz[b,e]oxepin, m. 146°; and 42% trans - 11 - (1-carboxamidoethylidene) - 6,11 - dihydrodibenz[b,e] - oxepin, m. 188-9° (iso-PrOH-ligroine) (cis isomer m. 218-19°, 31%). A solution of 25.3 g. I in 100 ml. tetrahydrofuran was treated with 25.3 g. granular Hg-Al, mixed dropwise with 50 ml. H<sub>2</sub>O, and the mixture kept overnight and worked up to give 86% 11-carboxamidomethyl-6,11-dihydrodibenz[b,e]oxepin, m. 140-1° (iso-PrOH). A mixture of 23.1 g. 5-cyanomethylene-10,11-dihydro-5H-dibenzo[a,d]cycloheptene and 23.1 g. KOH in a mixture of 100 ml. each of H<sub>2</sub>O and alc. was refluxed 4 hrs. and worked up to give 85% 5-carboxamidomethylene analog of II, m. 166-7°. III was prepared in this manner also. A solution of 2.7 g. Na in 20 ml. MeOH and 20 ml. HCONMe<sub>2</sub> (DMF) was added to a mixture of 5,6-dihydromorphanthridine-6,11-dione, 14.6 g. di-Et acetamidophosphonate, and 200 ml. DMF, and the mixture stirred 2 hrs. and worked up to give 60% 11-carboxamidomethyl-ene-5,6-dihydromorphanthridin-6-one, m. 315-18° (aqueous DMF). Also obtained was 5-methyl-11-carboxamidomethylene-5,6-di-hydromorphanthridin-6-one, m. 250-2° (EtOH). 5,6-Dihydro-morphanthridin-6-one-11-acetyl chloride (IV) (8 g.) in 50 ml. C<sub>6</sub>H<sub>6</sub> was stirred with 200 ml. concentrated aqueous NH<sub>3</sub> to give 72% corresponding amide, m. 254-5°. A mixture of 11.5 g. 5,6-dihydro-morphanthridine-6,11-dione and 16.8 g. di-Et carbethoxymethyl-phosphonate in 200 ml. DMF was stirred with a solution of 2.7 g. Na in 20 ml. MeOH and 20 ml. DMF 2 hrs. and worked up, neutralized with HOAc, poured into H<sub>2</sub>O, and filtered to give 75% 11-carbethoxymethylene-5,6-dihydromorphanthridin-6-one, m. 154-5° (iso-

PrOH). A solution of 9 g. of this in 200 ml. MeOH was hydrogenated over Raney Ni at atmospheric pressure to give 77% 11-carbethoxymethyl analog, m. 150-1° (iso-PrOH). Saponification of this gave the corresponding acid, m. 267-8° reaction of which with (COCl)<sub>2</sub> at ambient temperature gave IV. The subject compds. possess muscle relaxing, tranquilizing, and anticonvulsive activity.

IT **21607-74-9P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 21607-74-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo- (9CI) (CA

INDEX

NAME)



L11 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

AN 1969:68204 CAPLUS Full-text

DN 70:68204

TI Antidiabetic sulfonylureas and sulfonylsemicarbazides

IN Winter, Werner; Fauland, Erich; Stach, Kurt; Schmidt, Felix Helmut;  
Aum Mueller, Walter

PA Boehringer, C. F., und Soehne G.m.b.H.

SO S. African, 28 pp.

CODEN: SFXXAB

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	----	-----	-----
PI	ZA 6801636		19680812		
	DE 1618112			DE	
	FR 1556173			FR	
	GB 1153130			GB	
	US 3646009		19720000	US	
	US 3752851		19730000	US	
PRAI	DE		19670315		
AB	A solution of 4.5 g. p-[2-[2-(fluoren-9-yl)acetyl amino]ethyl]phenylsulfonyl carbamic acid Et ester, 100 ml. anhydrous PhMe, and 10 ml. HCONMe <sub>2</sub> was added to 1.3 g. 4-methylcyclohexylamine at 80°, the mixture boiled 15 min., cooled, and shaken with 300 ml. 0.2N NaOH, the precipitate suction-filtered off, washed with ether, and dissolved in 1:1 acetone-H <sub>2</sub> O, the solution diluted with H <sub>2</sub> O and acidified to pH 5.5 by addition of dilute HCl to give 74% I (Y = bond line, X = CHCH <sub>2</sub> , R = 4-methylcyclohexyl (Q)), m. 198-9° (MeOH). Similarly prepared I were (Y, X, R, % yield, and m.p. given): bond line, CHCH <sub>2</sub> , 4,4-dimethylpiperidino (Z), 58, 163-4°; bond line, CHCH <sub>2</sub> , 4-methylpiperidino (A), 76, 132-3°; CH <sub>2</sub> O, C:CH, Z, 53, 183-4°; CH <sub>2</sub> O, C:CH, Q, 65, 216-17°; CH <sub>2</sub> O, CHCH <sub>2</sub> , Q, 65, 216-17°; CH <sub>2</sub> O, CHCH <sub>2</sub> , Z, 44, 202-3°; O, CHCH <sub>2</sub> , Q, 48, 208-10°; O CHCH <sub>2</sub> , A, 45, 128-30°; CH <sub>2</sub> O, C:CH, Q, 42, - (K salt m. 161-3°); S, CHCH <sub>2</sub> , Z, 55, - [K salt m. 172-4° (decomposition)]; bond line, CHCH <sub>2</sub> , bicyclo[2.2.1]hept-2-yl, 58, 191-3°; bond line, CHCH <sub>2</sub> , cyclooctyl, 52, 192-3°; bond line, CHCH <sub>2</sub> , 1-adamantyl, 64, 201-2°; bond line, CHCH <sub>2</sub> , 1-cycloheptyl, 49, 178-80°. A mixture of 4 g. p-[2-(2-(6,11-dihydrodibenz[b,e]-oxepin-11-yl)acetyl amino)ethyl]benzenesulfonamide and 2.5 g. ground K <sub>2</sub> CO <sub>3</sub> in 100 ml. acetone was boiled and stirred 30 min., 1.5 g. cyclohexyl isocyanate added dropwise, the mixture refluxed and stirred 2 hrs., solvent distilled, residue taken up in H <sub>2</sub> O, clarified with charcoal, and filtered, and the filtrate acidified with dilute HCl to precipitate 66% I [Y = CH <sub>2</sub> O, X = CHCH <sub>2</sub> , R = cyclohexyl (E)], m. 201-2° (alc.). Similarly prepared are: I (Y = CH <sub>2</sub> O, X = CHCH <sub>2</sub> , R = Bu), m. 154-5°, and I (Y = bond line, X = C:CH, R = E), m. 199-200° from p-[2-[2-(fluoren-9-ylidene)-acetyl amino]ethyl]benzenesulfonamide, m. 215-16°. 3-[p-(2-Aminoethyl)phenylsulfonyl]-1-cyclohexylurea (6.5 g.; m. 211-12°) was suspended in 75 ml. pyridine and mixed with 5 g. xanthene-9-carboxylic acid chloride, the mixture kept 48 hrs., solvent distilled in vacuo, residue digested in dilute HCl, the solid filtered off by suction, washed with water, and purified by dissoln. in 0.2N NaOH and reprecip. with dilute HCl to give 81% I (Y = O, X = CH, R = E), m. 218-20° (MeOH). Similarly prepared were: I (Y = CH <sub>2</sub> CH <sub>2</sub> , X = CH, R = E), m. 202-3°, and I (Y = CH <sub>2</sub> S, X = CHCH <sub>2</sub> , R = A), m. 222-3°, from p-(H <sub>2</sub> NCH <sub>2</sub> CH <sub>2</sub> )C <sub>6</sub> H <sub>4</sub> SO <sub>2</sub> NHCONHA, m. 210-12°, and 6,11-				

dihydrodibenzo[b,e]thiepin-11-ylacetyl chloride. A mixture of 4.5 g. p-[2-(2-(thiaxanthen-9-yl)acetyl amino)ethyl]benzenesulfonamide and an equimolar amount NaH in 20 ml. HCONMe<sub>2</sub> was stirred 10 min., 2.0 g. pyrocarbonic acid diethyl ester added, the mixture kept 10-15 min., and 0.36 g. HCl in absolute EtOH added to give a solution of p-[2-(2-(thiaxanthen-9-yl)acetyl amino)ethyl]-phenylsulfonylcarbamic acid Et ester. To this solution was added 1.4 g. 4-methylcyclohexylamine in 100 ml. PhMe, the mixture boiled 25 min., cooled, and shaken with 0.2N NaOH, and dilute HCl added to precipitate 55% I (Y = S, X = CHCH<sub>2</sub>, R = Q), m. 198-9° (MeOH). Similarly prepared were I (Y, X, R, % yield, and m.p. given): S, CHCH<sub>2</sub>, Z, 48, 175-6°; bond line, C:CH, A, 63, 155-6°; CH<sub>2</sub>S, C:CH, Q, 70, 189-90°; CH<sub>2</sub>S, C:CH, A, 74, 210-11°; bond line, C:CH, Q, 72, 210-12°; CH:CH, CHCH<sub>2</sub>, Q, 67, 174-5°; bond line, NCH<sub>2</sub>, E, 64, 196-8°; bond line, NCH<sub>2</sub>, Q, 73, 198-200°; bond line, NCH<sub>2</sub>, A, 58, 154-6°; bond line, NCH<sub>2</sub>CH<sub>2</sub>, Q, 63, 206-8°; CH<sub>2</sub>CH<sub>2</sub>, C:CH, Q, 51, 194-5°; CH<sub>2</sub>CH<sub>2</sub>, CHCH<sub>2</sub>, Q, 63, 204-6°; CH<sub>2</sub>S, CHCH<sub>2</sub>, Q, 51, 153-5°; CH<sub>2</sub>S, CHCH<sub>2</sub>, Z, 50, 226-8°; CH<sub>2</sub>O, CHCH<sub>2</sub>, A, 48, 198-200°; bond line, CH, A, 62, 172-3°; bond line, CHCH<sub>2</sub>CH<sub>2</sub>, E, 60, 207-8°; bond line, CHCH<sub>2</sub>CH<sub>2</sub>, Q, 59, 210-12°; bond line, CHCH<sub>2</sub>CH<sub>2</sub>, Z, 52, 156-8°. Similarly prepared II were (Y, X, R, R<sub>1</sub>, R<sub>1</sub>, % yield, and m.p. given): CH<sub>2</sub>O, CHCH<sub>2</sub>, Q, MeO, H, 67, 172-4°; CH<sub>2</sub>O, CHCH<sub>2</sub>, Q, Me, H, 56, 179-80°; CH<sub>2</sub>O, CHCH<sub>2</sub>, Q, Cl, H, 72, 210-12°; bond line, CHCH<sub>2</sub>, Q, H, Me, 75, 202-3°; bond line, CHCH<sub>2</sub>, Q, H, MeO, 58, 168-9°; bond line, CHCH<sub>2</sub>, Q, H, Cl, 69, 218-20°. Similarly prepared was 71% 1-(4-methylcyclohexyl)-3-[p-(2-(2-(6,7-dihydro-12H-dibenzo[b,e]thiocin-12-yl)acetyl amino)ethyl)-phenylsulfonyl]urea, m. 184-6°. Similarly prepared I from the Na salt of p-[2-(2-(fluoren-9-yl)acetyl amino)ethyl]benzenesulfonamide were (Y, X, R, % yield, and m.p. given): bond line, CHCH<sub>2</sub>, 4-methoxycyclohexyl, 61%, 196-7°; bond line, CHCH<sub>2</sub>, tetrahydrothiapyran-4-yl, 53, 221-2°; bond line, CHCH<sub>2</sub>, 4,4-dimethylcyclohexyl, 67, 197-8°; bond line, CHCH<sub>2</sub>, 2-phenylethyl, 55, 186-7°; bond line, CHCH<sub>2</sub>, E, 54, 205-5°. Similarly prepared was 72% 1,1-hexamethylene-4-[p-(2-(2-(fluoren-9-yl)-acetyl amino)ethyl)phenylsulfonyl]semicarbazide, m. 110-12°. To prepare the acylaminoethylbenzenesulfonamides, 1 mole of the carboxylic acid chloride in question, dissolved in CH<sub>2</sub>Cl<sub>2</sub>, was added dropwise with stirring to a solution of 1 mole p-(H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>)-C<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>NH<sub>2</sub>, and 2 moles Na<sub>2</sub>CO<sub>3</sub> in H<sub>2</sub>O, the mixture stirred 1-2 hrs., dilute NaOH and H<sub>2</sub>O added to pH 10-11, CH<sub>2</sub>Cl<sub>2</sub> separated, and dilute HCl added to pH 8.8 to precipitate product which can be recrystd. from dilute alc. or 10:1:6 alc.-HCONMe<sub>2</sub>-H<sub>2</sub>O. To prepare the acylaminoethylphenylcarbamic acid Et esters, 1 mole of the acylaminoethylbenzenesulfonamide was dissolved in HCONMe<sub>2</sub>, mixed with 1 mole NaH, cooled, stirred 20 min., 1.2 mole pyrocarbonic acid diethyl ester added, the mixture heated and stirred at 60°, after cessation of CO<sub>2</sub> evolution, the solvent vacuum distilled, the residue dissolved in H<sub>2</sub>O, and dilute HCl added to pH 2-4 to precipitate product which may be recrystd. from alc. III and IV prepared were [Y, X, m.p. III, m.p. IV (R = H), and m.p. IV (R = CO<sub>2</sub>Et) given]: bond line, C:CH, 229-31°, 215-16°, -; bond line, CHCH<sub>2</sub>, 139-41°, 207-9°, 135-6°; O, CHCH<sub>2</sub>, 158-9°, 236-8°, 162-4°; S, CHCH<sub>2</sub>, 170-1°, 208-9°, 137-9°; CH<sub>2</sub>O, C:CH, 185-6°, 238-9°, 196-7°; CH<sub>2</sub>O, CHCH<sub>2</sub>, 117-19°; 178-9°, -; CH<sub>2</sub>O, C:Me, 178°, -, 128-30°; CH<sub>2</sub>S, C:CH, 179-81°, 210-12°, -; CH<sub>2</sub>S, CHCH<sub>2</sub>, 208-9°, 167-9°, -; CH:-CH, CHCH<sub>2</sub>, 167-8°, 197-8°, -; CH<sub>2</sub>CH<sub>2</sub>, CHCH<sub>2</sub>, 162-4°, 194-5°, -; CH<sub>2</sub>CH<sub>2</sub>, C:CH, 167-8°, 197-8°, -; bond line, NCH<sub>2</sub>, 215°, 254-5°, -; bond line, NCH<sub>2</sub>CH<sub>2</sub>, 166-8°, 173°, -; bond line, CH, 218-20°, 234-6°, -; bond line, CHCH<sub>2</sub>CH<sub>2</sub>, 145-6°, 186-8°, -. V and VI prepared were (Y, X, R<sub>1</sub>, R<sub>2</sub>, m.p. V, and m.p. VI given): bond line, CHCH<sub>2</sub>, H, Me, 126-7°, 210-11°; bond line, CHCH<sub>2</sub>, H, MeO, 170-1°, 158-60°; bond line,

CHCH<sub>2</sub>, Cl, H, -, 212-13°; CH<sub>2</sub>O, CHCH<sub>2</sub>, MeO, H, 119-20°, 138-40°; CH<sub>2</sub>O, CHCH<sub>2</sub>, Me, H, 110-11°, 169-70°; CH<sub>2</sub>O, CHCH<sub>2</sub>, Cl, H, 211-12°, 190-2°. Similarly prepared were: 6,7-dihydro-12H-dibenzo[b,e]thiocin-12-ylacetic acid, m. 193°, p-[2-(2-(6,7-dihydro-12H-dibenzo[b,e]thiocin-12-yl)acetyl)amino]ethylbenzenesulfonamide, m. 163-5°, 6,7-dihydro-12H-dibenzo[b,e]thiocin-12-ylideneacetic acid, m. 200-2°, and 6-oxo-5,6-dihydro-11H-dibenz[b,e]azepin-11-ylacetic acid, m. 267-8°.

IT **21607-74-9P**


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 21607-74-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo- (9CI) (CA

INDEX

NAME)






=> d his

(FILE 'HOME' ENTERED AT 16:21:12 ON 06 JAN 2005)  
FILE 'CAPLUS' ENTERED AT 16:21:19 ON 06 JAN 2005  
L1 1 S WO2001010847/PN  
L2 SEL L1 1- RN : 284 TERMS  
FILE 'STNGUIDE' ENTERED AT 16:21:46 ON 06 JAN 2005  
FILE 'REGISTRY' ENTERED AT 16:22:44 ON 06 JAN 2005  
L3 STRUCTURE UPLOADED  
L4 284 S L2  
L5 7 S L3 SUB=L4 SAM  
L6 133 S L3 FUL SUB=L4  
FILE 'CAPLUS' ENTERED AT 16:23:48 ON 06 JAN 2005  
L7 61 S L6  
FILE 'STNGUIDE' ENTERED AT 16:24:01 ON 06 JAN 2005  
FILE 'REGISTRY' ENTERED AT 16:25:03 ON 06 JAN 2005  
L8 STRUCTURE UPLOADED  
L9 6 S L8 SAM SUB=L6  
L10 132 S L8 FUL SUB=L6  
FILE 'CAPLUS' ENTERED AT 16:26:06 ON 06 JAN 2005  
L11 6 S L10

=> d l3; d l8; log y  
L3 HAS NO ANSWERS  
L3 STR



Structure attributes must be viewed using STN Express query preparation.

L8 HAS NO ANSWERS  
L8 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.44	247.69
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.38	-4.38

STN INTERNATIONAL LOGOFF AT 16:28:24 ON 06 JAN 2005

*electer group*

L7 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:142712 CAPLUS Full-text

DN 136:200186

TI Preparation of dibenzo[b,e]azepines as  $\alpha\text{V}\beta 3$  integrin ligands

IN Geneste, Herve; Kling, Andreas; Lauterbach, Arnulf; Graef, Claudia  
Isabella; Subkowski, Thomas; Hornberger, Wilfried

PA Basf Aktiengesellschaft, Germany

SO PCT Int. Appl., 157 pp.


CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014320	A2	20020221	WO 2001-EP9224	20010809
	WO 2002014320	A3	20020725		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	DE 10039998	A1	20020221	DE 2000-10039998	20000811
	AU 2001091756	A5	20020225	AU 2001-91756	20010809
	CA 2419078	AA	20030210	CA 2001-2419078	20010809
	EP 1307443	A2	20030507	EP 2001-971899	20010809
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004506637	T2	20040304	JP 2002-519460	20010809
	US 2004077638	A1	20040422	US 2003-344449	20030908
PRAI	DE 2000-10039998	A	20000811		
	DE 2000-10028575	A	20000614		
	WO 2001-EP9224	W	20010809		
OS	MARPAT 136:200186				
GI					



AB The invention relates to novel compds. which bind to integrin receptors, in particular as ligands for the  $\alpha\text{V}\beta 3$  integrin receptor, the use thereof and pharmaceutical prepsns. containing said compds. BGL [L = UT; T = CO<sub>2</sub>H, group hyrdolyzable to CO<sub>2</sub>H, isostere of CO<sub>2</sub>H; U = Xa(CR<sub>1</sub>R<sub>2</sub>)<sub>b</sub>, CR<sub>1</sub>:CR<sub>2</sub>, C.tplbond.C, etc.; a = 0, 1; b = 0-2; X = CR<sub>3</sub>R<sub>4</sub>, NR<sub>5</sub>, O, S; R<sub>1</sub>-R<sub>4</sub> = T, H, OH, -CONH<sub>2</sub>, halo, amino, substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkylaminocarbonyl, etc.; R<sub>5</sub> = H, (substituted) alkyl,

cycloalkyl, alkoxy, carbonyl, alkylsulfonyl, etc.; G = Q1; Ar = atoms to form a (substituted) (anellated) (heterocyclic) 3-10 membered aryl ring; D = atoms to form a (substituted) (anellated) (unsatd.) (aromatic) 3-10 membered (heterocyclic) ring; X = CR11, N, C; W = YNR15; Y = CO, CS, C:NR12, CR13R14; R11 = H, halo, OH, (substituted) alkyl, alkoxy; R12 = H, OH, (substituted) alkyl, alkoxy, cycloalkyl, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy; R13, R14 = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy; R13R14 = OCH2CH2O, OCH2O, (substituted) cycloalkyl; R15 = R151, AR152, etc.; R151 = COR152, CSR152, NO2, tetrazolyl, etc.; R152 = H, (substituted) cycloalkyl, aryl, heteroaryl, etc.; R153 = H, OH, (substituted) alkyl, alkoxy, aralkyl, aralkoxy, etc.; B = structure element containing ≥1 atom which can function as an acceptor in H bond formation under physiol. conditions], were prepared as αVβ3 integrin ligands (no data). Thus, ethyldiisopropylamine and HATU were added to a 0° solution of 11'-(2-methoxy-2-oxoethyl)-5-methyl-6-oxo-6,11-dihydro-5H-dibenzo[b,e]azepine-3-carboxylic acid (preparation given) in CH2Cl2; the mixture was stirred 1 h at 0° and 7-(4-aminobutyl)-1,2,3,4-tetrahydro[1,8]naphthyridine bistrifluoroacetate and ethyldiisopropylamine were added followed by stirring for 1 h at 0° overnight at room temperature to give Me [5-methyl-6-oxo-3-[[[4-[5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl]butyl]amino]carbonyl]-6,11-dihydro-5H-dibenzo[b,e]azepin-11-yl]acetate.


IT 400712-67-6P 400712-68-7P 400712-69-8P  
 400712-70-1P 400712-71-2P 400712-72-3P  
 400712-73-4P 400712-74-5P 400712-75-6P  
 400712-78-9P 400712-79-0P 400712-82-5P  
 400712-83-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of dibenzazepines as αVβ3 integrin ligands)


RN 400712-67-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[4-(2-pyridinylamino)butoxy]- (9CI) (CA INDEX NAME)



RN 400712-68-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[3-(2-pyridinylamino)propoxy]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 400712-69-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 400712-70-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[[[3-(2-pyridinylamino)propyl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)




● Na


RN 400712-71-2 CAPLUS

CN Acetic acid, -[3-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]carbo


nyl]-5,6-dihydro-5-methyl-6-oxo-11H-dibenz[b,e]azepin-11-ylidene]-,  
methyl  
ester (9CI) (CA INDEX NAME)



RN 400712-72-3 CAPLUS  
CN Acetic acid, [3-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]carbo-nyl]-5,6-dihydro-5-methyl-6-oxo-11H-dibenz[b,e]azepin-11-ylidene]- (9CI)  
(CA INDEX NAME)




RN 400712-73-4 CAPLUS  
CN Acetic acid, [5,6-dihydro-5-methyl-6-oxo-3-[3-(2-pyridinylamino)propoxy]-11H-dibenz[b,e]azepin-11-ylidene]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 400712-74-5 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 400712-75-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[1H-benzimidazol-2-ylmethyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, monosodium salt (9CI) (CA INDEX NAME)




● Na

RN 400712-78-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[trans-4-(1H-benzimidazol-2-ylamino)cyclohexylmethyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 400712-79-0 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[trans-4-(1H-benzimidazol-2-ylamino)cyclohexyl]methyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 400712-82-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[4-(1H-benzimidazol-2-ylamino)butyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 400712-83-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[4-(1H-benzimidazol-2-ylamino)butyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo- (9CI) (CA INDEX NAME)



IT 400712-92-7P 400712-93-8P 400712-94-9P  
400712-95-0P 400712-96-1P 400712-99-4P

400713-00-0P 400713-04-4P 400713-05-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);


RACT

(Reactant or reagent)

(preparation of dibenzoazepines as  $\alpha V\beta 3$  integrin ligands)


RN 400712-92-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-3-[4-[(1-oxido-2-pyridinyl)amino]butoxy]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-93-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[4-(2-pyridinylamino)butoxy]-, methyl ester (9CI) (CA INDEX NAME)



RN 400712-94-9 CAPLUS


CN Acetic acid, [5,6-dihydro-5-methyl-3-[3-[(1-oxido-2-pyridinyl)amino]propoxy]-6-oxo-11H-dibenz[b,e]azepin-11-ylidene]-, methyl ester (9CI) (CA INDEX NAME)






RN 400712-95-0 CAPLUS

CN Acetic acid, [5,6-dihydro-5-methyl-6-oxo-3-[3-(2-pyridinylamino)propoxy]-11H-dibenz[b,e]azepin-11-ylidene]-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-96-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-[3-(2-pyridinylamino)propoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 400712-99-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 400713-00-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-methyl-6-oxo-3-  
[[[3-(2-pyridinylamino)propyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX  
NAME)




RN 400713-04-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[5-(1H-benzimidazol-2-  
ylamino)pentyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl  
ester  
(9CI) (CA INDEX NAME)




RN 400713-05-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 3-[[[1H-benzimidazol-2-  
ylmethyl]amino]carbonyl]-6,11-dihydro-5-methyl-6-oxo-, methyl ester  
(9CI)  
(CA INDEX NAME)



L7 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2002:97692 CAPLUS Full-text  
 DN 137:103383  
 TI Synthesis and SAR of N-substituted dibenzazepinone derivatives as novel  
 potent and selective  $\alpha\text{V}\beta 3$  antagonists  
 AU Kling, Andreas; Backfisch, Gisela; Delzer, Jurgen; Geneste, Herve;  
 Graef, Claudia; Holzenkamp, Uta; Hornberger, Wilfried; Lange, Udo E. W.;  
 Lauterbach, Arnulf; Mack, Helmut; Seitz, Werner; Subkowski, Thomas  
 CS Knoll GmbH, Ludwigshafen, D-67008, Germany  
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(3), 441-446  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 137:103383  
 GI



AB Substituted oxodibenzazepineacetic acids substituted with guanidines or  
 guanidine pharmacophores such as I are prepared as potential  $\alpha\text{V}\beta 3$   
 (vitronectin receptor) antagonists. The oxodibenzazepineacetic acid  
 core II is prepared in 5 steps from 9,10-anthraquinone; coupling of II  
 with guanidine or guanidine pharmacophore-substituted amines such as III  
 followed by hydrolysis of the Me ester yields compds. such as I.  
 Structure-activity relationships are determined for the guanidine or  
 guanidine pharmacophore-substituted oxodibenzazepineacetic acids,  
 varying the linker between the guanidine pharmacophore and the  
 oxodibenzazepine and the choice of guanidine pharmacophore. Compound I  
 and a second guanidine pharmacophore-substituted oxodibenzazepineacetic  
 acid are found to be highly active inhibitors of the vitronectin  
 receptor in vitro and are found to be bioavailable in ADME assays.  
 IT **326401-69-8P 326401-92-7P 443332-42-1P**  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (preparation of a guanidine or guanidine pharmacophore-substituted

oxodibenzazepineacetic acid and lack of activity as a potential  
 $\alpha\text{v}\beta 3$  receptor antagonist)


RN 326401-69-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[4-


[(1-oxo-3-phenylpropyl)amino]phenyl)methyl]amino]ethyl]- (9CI) (CA  
 INDEX

NAME)

PAGE 1-A




PAGE 2-A




RN 326401-92-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-[[4-  
 [[[ (phenylmethyl) amino] carbonyl] amino] phenyl] methoxy] ethyl]- (9CI) (CA  
 INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 443332-42-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-[[[4-  
 [[[phenylmethyl]amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A





IT 326398-90-7P 326399-16-0P 326399-52-4P  
 326399-63-7P 326399-69-3P 326399-78-4P  
 326399-83-1P 326400-55-9P 326400-65-1P  
 326400-70-8P 326401-04-1P 326401-08-5P  
 326401-18-7P 326401-26-7P 326401-31-4P  
 326401-36-9P 326401-41-6P 326401-74-5P  
 326401-97-2P 326471-38-9P 443332-00-1P  
 443332-07-8P 443332-29-4P 443332-52-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)


(preparation of guanidine or guanidine pharmacophore-substituted  
 oxodibenzazepineacetic acids as potential  $\alpha\text{V}\beta\text{3}$  receptor  
 antagonists)


RN 326398-90-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-


3-

pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
 NAME)






RN 326399-16-0 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[(1H-benzimidazol-2-yl)methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326399-52-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326399-63-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

NAME)



RN 326399-69-3 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[4-(1H-imidazo[4,5-b]pyridin-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326399-78-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-2-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)






RN 326399-83-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-yl)phenyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-55-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326400-65-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326400-70-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-


ylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326401-04-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[4-(1H-benzimidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-08-5 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[4-  
 [(2-pyridinylamino)methyl]-2-thienyl)methyl]amino]ethyl]- (9CI) (CA  
 INDEX  
 NAME)



PAGE 1-A



PAGE 2-A



RN 326401-18-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[4-  
 (2-pyridinylamino)phenyl)methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326401-26-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-


[[ [ 4-

[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI)  
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A




```


RN      326401-31-4    CAPLUS
CN      5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-
        [(aminoiminomethyl)amino]phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-
6-      oxo- (9CI)    (CA INDEX NAME)

```

PAGE 1-A



PAGE 2-A



RN 326401-36-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5-chloro-1H-benzimidazol-

2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA


INDEX

NAME)

PAGE 1-A




PAGE 2-A




RN 326401-41-6 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5,6-dimethyl-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A






PAGE 2-A




RN 326401-74-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[[ (phenylmethoxy) carbonyl] amino] phenyl] methyl] amino] ethyl]- (9CI) (CA  
INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-97-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[4-[4-  
[[[ (phenylmethyl) amino] carbonyl] amino] phenyl] butyl]- (9CI) (CA INDEX  
NAME)



RN 326471-38-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 443332-00-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 443332-07-8 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[3-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 443332-29-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[4-  
 [[[ (phenylmethyl)amino]carbonyl]oxy]phenyl]methyl]amino]ethyl]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 443332-52-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[trans-4-(1H-benzimidazol-  
 2-  
 ylamino)cyclohexyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI)  
 (CA INDEX NAME)

Relative stereochemistry.



IT 326400-60-6P 326401-22-3P 326408-08-6P  
 326408-33-7P 443331-29-1P 443331-31-5P  
 443331-34-8P 443331-37-1P 443331-42-8P  
 443331-47-3P 443331-50-8P 443331-53-1P  
 443331-56-4P 443331-59-7P 443331-62-2P  
 443331-65-5P 443331-68-8P 443331-73-5P  
 443331-76-8P 443331-79-1P 443331-84-8P  
 443331-87-1P 443331-90-6P 443331-93-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT

(Reactant or reagent)


(preparation of guanidine or guanidine pharmacophore-substituted  
 oxodibenzazepineacetic acids as potential  $\alpha\text{V}\beta\text{3}$  receptor  
 antagonists)

RN 326400-60-6 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-22-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[4-  
 [[[ (phenylmethyl) amino] carbonyl] amino] phenyl] methyl] amino] ethyl]-,  
 methyl  
 ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326408-08-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-  
 3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326408-33-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
 2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI)  
 (CA INDEX NAME)



RN 443331-29-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 443331-31-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-yl)phenyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A


||

RN 443331-34-8 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 443331-37-1 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[4-(1H-benzimidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 443331-42-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[3-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
(9CI) (CA INDEX NAME)



RN 443331-47-3 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
(9CI)  
(CA INDEX NAME)



PAGE 1-A


U

RN 443331-50-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
 2-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)



U

RN 443331-53-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[4-(1H-  
 imidazo[4,5-b]pyridin-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo-,  
 methyl ester (9CI) (CA INDEX NAME)




RN 443331-56-4 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-

[[[4-

[(2-pyridinylamino)methyl]-2-thienyl)methyl]amino]ethyl]-, methyl ester  
(9CI) (CA INDEX NAME)

PAGE 1-A







RN 443331-59-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester

(9CI)

(CA INDEX NAME)




RN 443331-62-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5-chloro-1H-benzimidazol-


-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 443331-65-5 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5,6-dimethyl-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 443331-68-8 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-  
6- [(aminoiminomethyl)amino]phenyl)methyl]amino]-2-oxoethyl]-6,11-dihydro-  
oxo-, methyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 443331-73-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[[[(phenylmethyl)amino]carbonyloxy]phenyl]methyl]amino]ethyl]-, methyl  
ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 443331-76-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[[ (phenylmethoxy) carbonyl] amino] phenyl] methyl] amino] ethyl]-, methyl  
ester  
(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 443331-79-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[(1-oxo-3-phenylpropyl)amino]phenyl]methyl]amino]ethyl]-, methyl ester  
(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 443331-84-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-


[[[4-

(2-pyridinylamino)phenyl]methyl]amino]ethyl]-, methyl ester (9CI) (CA  
INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 443331-87-1 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-ylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)  
(CA INDEX NAME)




RN 443331-90-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI)  
 (CA INDEX NAME)



RN 443331-93-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[trans-4-(1H-benzimidazol-2-ylamino)cyclohexyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)


Relative stereochemistry.



RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2001:115130 CAPLUS Full-text  
 DN 134:178474  
 TI Preparation of oxobenzazepinealkanoates and analogs as integrin receptor antagonists  
 IN Kling, Andreas; Geneste, Herve; Lange, Udo; Lauterbach, Arnulf; Graef, Claudia Isabella; Subkowski, Thomas; Holzenkamp, Uta; Mack, Helmut; Sadowski, Jens; Hornberger, Wilfried; Laux, Volker  
 PA BASF Aktiengesellschaft, Germany  
 SO PCT Int. Appl., 158 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010847	A2	20010215	WO 2000-EP7440	20000801
	WO 2001010847	A3	20011101		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 19936780	A1	20010215	DE 1999-19936780	19990809
	CA 2379977	AA	20010215	CA 2000-2379977	20000801
	EP 1202988	A2	20020508	EP 2000-958347	20000801
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	BR 2000013265	A	20020514	BR 2000-13265	20000801
	TR 200200357	T2	20020923	TR 2002-200200357	20000801
	JP 2003506441	T2	20030218	JP 2001-515313	20000801
	BG 106395	A	20021229	BG 2002-106395	20020206
	NO 2002000644	A	20020318	NO 2002-644	20020208
PRAI	DE 1999-19936780	A	19990809		
	WO 2000-EP7440	W	20000801		
OS	MARPAT 134:178474				
GI					



AB — RZZ1R1 [I; R = group-contg, ≥1 non-H H-bonding atom; R1 = CO2H, or group hydrolyzable to CO2H; Z = e.g., (hetero)annelated 2-oxo-1-benzazepin-

1,5-diyl; Z1 = bond, (un)substituted NHCH<sub>2</sub>, -OCH<sub>2</sub>, -alkylene, -CH:CH, etc.] were prepared. Thus, Me 11-methoxycarbonylmethyl-6-oxo-6,11-dihydro-5H-dibenz[b,e]azepine-5-acetate (preparation given) was amidated by N-(2-aminoethyl)pyridine-2-amine to give, after saponification, title compound II. Data for biol. activity of I were given.



IT 326398-79-2P 326398-84-9P 326398-90-7P  
 326399-01-3P 326399-07-9P 326399-11-5P  
 326399-17-1P 326399-23-9P 326399-27-3P  
 326399-31-9P 326399-36-4P 326399-42-2P  
 326399-47-7P 326399-52-4P 326399-64-8P  
 326399-69-3P 326399-73-9P 326399-78-4P  
 326399-83-1P 326400-13-9P 326400-18-4P  
 326400-23-1P 326400-28-6P 326400-32-2P  
 326400-41-3P 326400-45-7P 326400-50-4P  
 326400-55-9P 326400-60-6P 326400-65-1P  
 326400-70-8P 326400-74-2P 326400-79-7P  
 326400-84-4P 326400-88-8P 326400-94-6P  
 326400-99-1P 326401-04-1P 326401-08-5P  
 326401-13-2P 326401-18-7P 326401-22-3P  
 326401-26-7P 326401-32-5P 326401-36-9P  
 326401-41-6P 326401-46-1P 326401-50-7P  
 326401-54-1P 326401-59-6P 326401-64-3P  
 326401-69-8P 326401-74-5P 326401-82-5P  
 326401-92-7P 326401-97-2P 326402-06-6P  
 326402-11-3P 326402-16-8P 326402-21-5P  
 326402-26-0P 326402-31-7P 326402-35-1P  
 326402-40-8P 326402-44-2P 326402-48-6P  
 326402-52-2P 326402-57-7P 326402-62-4P  
 326402-66-8P 326402-71-5P 326402-76-0P  
 326402-80-6P 326402-85-1P 326402-90-8P  
 326402-94-2P 326402-99-7P 326403-04-7P  
 326403-08-1P 326403-13-8P 326403-18-3P  
 326403-22-9P 326403-28-5P 326403-32-1P  
 326403-37-6P 326403-42-3P 326403-47-8P  
 326403-61-6P 326403-66-1P 326403-71-8P  
 326403-76-3P 326404-18-6P 326404-23-3P  
 326404-27-7P 326404-31-3P 326404-36-8P  
 326471-39-0P

RL: BAC (Biological activity or effector, except adverse); BSU  
 (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic  
 use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of oxobenzazepinealkanoates and analogs as integrin  
 receptor  
 antagonists)


RN 326398-79-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-  
 (2-  
 pyridinylamino)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)






RN 326398-84-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-  
 3- pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
 NAME)

PAGE 1-A




PAGE 2-A




RN 326399-01-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[[4,5-dihydro-1H-  
 imidazol-2-yl]amino]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
 NAME)

PAGE 1-A



PAGE 2-A




RN 326399-07-9 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(4,5-dihydro-1H-imidazol-2-yl)-3-pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-,  
monoacetate  
(9CI) (CA INDEX NAME)


CM 1

CRN 326399-06-8  
CMF C27 H25 N5 O4

PAGE 1-A




PAGE 2-A



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 326399-11-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-


[[[1-

(2-pyridinyl)-4-piperidinyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326399-17-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[(1H-benzimidazol-2-ylmethyl)amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI) (CA INDEX NAME)

CM 1


CRN 326399-16-0

CMF C26 H22 N4 O4



CM 2


CRN 64-19-7  
CMF C2 H4 O2



RN 326399-23-9 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[(1H-imidazo[4,5-b]pyridin-2-ylmethyl)amino]-2-oxoethyl]-6-oxo-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 326399-22-8  
CMF C25 H21 N5 O4



CM 2


CRN 64-19-7  
CMF C2 H4 O2




RN 326399-27-3 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-[[2-

(2-

PAGE 1-A



PAGE 2-A




RN

CN


(2-

pyridinyl)-1-piperazinyl]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 326399-36-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[3-[[[4-(1H-benzimidazol-2-yl)-2-thienyl]methyl]amino]-3-oxopropyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)






RN 326399-42-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinylamino)methyl]-1-piperidiny]ethyl]-, monoacetate (9CI) (CA  
INDEX  
NAME)


CM 1

CRN 326399-41-1  
CMF C29 H30 N4 O4

PAGE 1-A




PAGE 2-A




CM 2

CRN 64-19-7  
CMF C2 H4 O2




RN 326399-47-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
[[ (phenylmethyl) amino] carbonyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX  
NAME)



RN 326399-52-4 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(1H-benzimidazol-2-yl)-  
2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
NAME)



RN 326399-64-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
 2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI)  
 (CA INDEX NAME)


CM 1

CRN 326399-63-7  
 CMF C30 H24 N4 O4 S




CM 2

CRN 64-19-7  
 CMF C2 H4 O2




RN 326399-69-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[4-(1H-imidazo[4,5-b]pyridin-2-yl)-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo-  
 (9CI) (CA INDEX NAME)




RN 326399-73-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-,  
monohydrochloride  
(9CI) (CA INDEX NAME)

PAGE 1-A






RN 326399-78-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
 2-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
 NAME)




RN 326399-83-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)phenyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-13-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(1H-imidazol-2-ylamino)-3-oxopropyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)


PAGE 1-A





RN 326400-18-4 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
[[[(phenylmethyl)amino]carbonyl]amino]methyl]-1-piperidinyl]ethyl]-  
(9CI)  
(CA INDEX NAME)




RN 326400-23-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-  
[[[1-  
(2-pyridinyl)-4-piperidinyl]methyl]amino]propyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326400-28-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[3-oxo-3-  
[[[1-  
[[[(phenylmethyl)amino]carbonyl]-4-piperidinyl]methyl]amino]propyl]-  
(9CI)


(CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 326400-32-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[3-[[[5-(1H-benzimidazol-2-yl)-  
2- thienyl]methyl]amino]-3-oxopropyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326400-41-3 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
 [[[1-  
 [[(phenylmethyl)amino]carbonyl]-4-piperidinyl]methyl]amino]ethyl]- (9CI)  
 (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326400-45-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-

[[[(phenylmethyl)amino]carbonyl]amino]methyl]phenyl]methyl]amino]ethyl]-  
(9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326400-50-4 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinylamino)-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326400-55-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-60-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-ylamino)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326400-65-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[5-(1H-benzimidazol-2-ylamino)pentyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326400-70-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(1H-benzimidazol-2-ylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326400-74-2 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[3-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326400-79-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[(1H-benzimidazol-2-ylamino)methyl]-1-piperidinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326400-84-4 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[2-(2-pyridinylamino)-4-thiazolyl]methyl]amino]ethyl]- (9CI) (CA INDEX  
NAME)



PAGE 1-A



PAGE 2-A




ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE

RN 326400-88-8 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[2-

(2-pyridinylamino)-5-thiazolyl]methyl]amino]ethyl]- (9CI) (CA INDEX  
NAME)

PAGE 1-A



PAGE 2-A



ONE OR MORE TAUTOMERIC DOUBLE BONDS NOT DISPLAYED IN THE STRUCTURE


RN 326400-94-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[2-  
[(aminoiminomethyl)amino]-  
4-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 326400-93-5


CMF C23 H22 N6 O4 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 326400-99-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[2-[(aminoiminomethyl)amino]-

5-thiazolyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA

INDEX


NAME)




RN 326401-04-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-[4-(1H-benzimidazol-2-yl)phenyl]ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-08-5 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[(2-pyridinylamino)methyl]-2-thienyl)methyl]amino]ethyl]- (9CI) (CA  
INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326401-13-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[methyl[2-(2-  
pyridinylamino)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-18-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-(2-pyridinylamino)phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 326401-22-3 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-

[[[4-


[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-, methyl

ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 326401-26-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-

[[[4-


[[[(phenylmethyl)amino]carbonyl]amino]phenyl)methyl]amino]ethyl]- (9CI)  
(CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 326401-32-5 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-  
6- [(aminoiminomethyl)amino]phenyl)methyl]amino]-2-oxoethyl]-6,11-dihydro-  
oxo-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)  
CM 1  
CRN 326401-31-4  
CMF C26 H25 N5 O4

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 326401-36-9 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5-chloro-1H-benzimidazol-

2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA


INDEX

NAME)

PAGE 1-A





PAGE 2-A




RN 326401-41-6 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(5,6-dimethyl-1H-benzimidazol-2-yl)phenyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A






RN 326401-46-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[3-(2-pyridinylamino)propyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326401-50-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyridinylamino)ethyl]-1-piperidinyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-54-1 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
[2-  
(2-pyridinylamino)ethyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326401-59-6 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[3-

[2-(2-pyridinylamino)ethyl]-1-pyrrolidinyl]ethyl]-, methyl ester (9CI) (CA  
INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-64-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[3-(2-pyridinylamino)ethyl]-1-pyrrolidinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326401-69-8 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[[4-  
[(1-oxo-3-phenylpropyl)amino]phenyl)methyl]amino]ethyl]- (9CI) (CA  
INDEX  
NAME)



PAGE 1-A



PAGE 2-A




RN 326401-74-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-


[[[4-

[[ (phenylmethoxy) carbonyl] amino] phenyl] methyl] amino] ethyl]- (9CI) (CA  
INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326401-82-5 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[5-  
 [[[ (phenylmethyl) amino] carbonyl] amino] pentyl]- (9CI) (CA INDEX NAME)




RN 326401-92-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-[[4-  
 [[[ (phenylmethyl) amino] carbonyl] amino] phenyl] methoxy] ethyl]- (9CI) (CA  
 INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326401-97-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[4-[4-  
 [[[ (phenylmethyl) amino] carbonyl] amino] phenyl] butyl]- (9CI) (CA INDEX  
 NAME)




RN 326402-06-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(4-methyl-  
 1H-

imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-11-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-16-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(3-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-21-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-26-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[1-methyl-2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)



RN 326402-31-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[1-ethyl-2-pyrrolidinyl)methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-35-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(4-pyridinylmethyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326402-40-8 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 326402-44-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(diethylamino)ethyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-48-6 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[4-[2-(4-morpholinyl)ethyl]-1-piperazinyl]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 2-A




RN 326402-52-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-57-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(2-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-62-4 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[2-(4-morpholinyl)ethyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-66-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[3-(dibutylamino)propyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-71-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(4-pyridinyl)-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 326402-76-0 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[4-[3-(4-morpholinyl)propyl]-1-piperazinyl]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

CH<sub>2</sub>-CO<sub>2</sub>H


RN 326402-80-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[3-(2-methyl-1H-imidazol-1-yl)propyl]amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-85-1 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[(4-pyridinylmethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-90-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[(1-methyl-4-piperidinyl)amino]-2-oxoethyl]-6-oxo- (9CI) (CA INDEX NAME)




RN 326402-94-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(1-piperidinyl)ethyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 326402-99-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(1-pyrrolidinyl)propyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326403-04-7 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(dimethylamino)ethyl]-  
 1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326403-08-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[3-(dimethylamino)propyl]-


1-

piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326403-13-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[2-(dipropylamino)ethyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-18-3 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-(1-piperidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)




PAGE 1-A



PAGE 2-A




RN 326403-22-9 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[3-(dipropylamino)propyl]-  
 1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-28-5 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(dibutylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 326403-32-1 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1-piperazinyl]ethyl]- (9CI) (CA INDEX NAME)






RN 326403-37-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[3-(diethylamino)propyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-42-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[2-(dimethylamino)ethyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-47-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[4-(dimethylamino)butyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)




RN 326403-61-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326403-66-1 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[[4-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]methyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 326403-71-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[2-  
(2-pyridinylamino)ethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326403-76-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-propanoic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-  
[[2-(2-pyridinylamino)ethyl]amino]ethyl]-, monosodium salt (9CI) (CA INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 326404-18-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[[4-[[[4-(1H-benzimidazol-2-yl)phenyl]methyl]amino]carbonyl]-2-thiazolyl]methyl]-6,11-dihydro-6-oxo-(9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 326404-23-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[4-[(2-pyridinylamino)methyl]-1-piperidinyl]carbonyl]-2-thiazolyl]methyl]-  
(9CI)


(CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 326404-27-7 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-  
[[[(phenylmethyl)amino]carbonyl]amino]phenyl)methyl]amino]carbonyl]-2-  
thiazolyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 326404-31-3 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-  
[(2-  
pyridinylamino)methyl]phenyl)methyl]amino]carbonyl]-2-thiazolyl)methyl]-  
(9CI) (CA INDEX NAME)




RN 326404-36-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[[4-[[[4-(2-pyridinylamino)methyl]-2-thienyl]methyl]amino]carbonyl]-2-thiazolyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 326471-39-0 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, monoacetate (9CI)  
(CA INDEX NAME)


CM 1

CRN 326471-38-9  
CMF C24 H22 N4 O4 S



CM 2

CRN 64-19-7  
CMF C2 H4 O2



IT 326407-99-2P 326408-04-2P 326408-08-6P  
326408-13-3P 326408-23-5P 326408-28-0P  
326408-33-7P 326408-41-7P 326408-46-2P  
326408-54-2P 326410-02-0P 326410-07-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);

RACT


(Reactant or reagent)

(preparation of oxobenzazepinealkanoates and analogs as integrin  
receptor  
antagonists)


RN 326407-99-2 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[[2-(2-  
(2-pyridinylamino)ethyl]amino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 326408-04-2 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
(2-pyridinyl)-1-piperazinyl]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 326408-08-6 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[6-(1H-benzimidazol-2-yl)-  
 3- pyridinyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
 (9CI) (CA INDEX NAME)


PAGE 1-A





RN 326408-13-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[4-[(1,1-dimethylethoxy)carbonyl]-1-piperazinyl]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 326408-23-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(aminothioxomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester (9CI)


(CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 326408-28-0 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[5-(aminoiminomethyl)-2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
(9CI)

(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 326408-33-7 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-acetic acid, 5-[2-[[[4-(1H-benzimidazol-2-yl)-  
2-thienyl]methyl]amino]-2-oxoethyl]-6,11-dihydro-6-oxo-, methyl ester  
(9CI)  
(CA INDEX NAME)




RN 326408-41-7 CAPLUS



CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[[3-(1H-imidazol-2-ylamino)-3-oxopropyl]amino]-2-oxoethyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A






RN 326408-46-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-5-[2-[[[5-(hydroxyamino)iminomethyl]-2-thienyl]methyl]amino]-2-oxoethyl]-6-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 326408-54-2 CAPLUS  
 CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[5-[[[(phenylmethyl)amino]carbonyl]amino]pentyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 326410-02-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-(1-piperazinyl)ethyl]-, methyl ester, mono(trifluoroacetate) (9CI) (CA


INDEX

NAME)

CM 1

CRN 326410-01-9


CMF C23 H25 N3 O4



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 326410-07-5 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-5-[2-oxo-2-[4-  
[[ (phenylmethyl)amino]carbonyl]-1-piperazinyl]ethyl]-, methyl ester

(9CI)

(CA INDEX NAME)



L7 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1989:632774 CAPLUS Full-text  
 DN 111:232774  
 TI Preparation of tricyclic lactams and analogs as muscarinic antagonists  
 IN Turconi, Marco; Donetti, Arturo; Cereda, Enzo; Quintero, Myrna Gil;  
 Schiavi, Giovanni Battista; Micheletti, Rosamaria  
 PA Istituto De Angeli S.p.A., Italy  
 SO Eur. Pat. Appl., 46 pp.  
 CODEN: EPXXDW

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 309422	A2	19890329	EP 1988-830374	19880919
	EP 309422	A3	19900110		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DD 282689	A5	19900919	DD 1988-319831	19880915
	DK 8805226	A	19890322	DK 1988-5226	19880920
	FI 8804305	A	19890322	FI 1988-4305	19880920
	NO 8804174	A	19890322	NO 1988-4174	19880920
	JP 01132567	A2	19890525	JP 1988-236178	19880920
	AU 8822380	A1	19890323	AU 1988-22380	19880921
PRAI	IT 1987-21978	A	19870921		

OS MARPAT 111:232774

GI For diagram(s), see printed CA Issue.

AB Title compds. I [R = H, halo; X = N, CH; W = NHCO, CH:CH, (CH<sub>2</sub>)<sub>2</sub>, O, S; R<sub>1</sub> = H, C<sub>1</sub>-4 alkyl; n = 0, 1; Y = S, CH; A = C, N; B = CH when A ≠ N, CO<sub>2</sub>, CO, CH<sub>2</sub>; m = 0-3; Z = NH, CO, CO<sub>2</sub>, CH, bond; p,q = 0, 1; Q = (homo)piperazinyl, piperidinyl, troyl, tetrahydropyrimidinyl, the above groups may be substituted by a C<sub>1</sub>-4 alkyl or an amino; R = CR<sub>2</sub>:NR<sub>3</sub>; R<sub>2</sub> = H, C<sub>1</sub>-4 alkyl, (C<sub>1</sub>-4 alkyl- or Ph-substituted) amino; R<sub>3</sub> = C<sub>1</sub>-8 alkyl, H (provided that the bond of QR is a C-C bond or AB = C:CH); R<sub>2</sub>R<sub>3</sub> = atoms to form a 5-membered ring] are prepared for treatment of motility disorders of the gastrointestinal or urogenital tract and peptic ulcer disorders. A mixture of 5,10-dihydro-5-[2-piperazin-1-yl]acetyl-11H-dibenzo[b,e][1,4]-diazepin-11-one and H<sub>2</sub>NC(:NH)SMe.H<sub>2</sub>SO<sub>4</sub> in EtOH was refluxed to give the 4-guanylpiperazinyl analog isolated as its 2 HCl salt. The latter salt showed a dissociation constant (K<sub>D</sub>) of 6 nM for displacement of 3H-pirenzepine from cerebral cortex homogenate of rats. Tablets were formulated containing I 20, lactose 247, cornstarch 30, and Mg stearate 3 mg.


IT 122860-50-8P 122860-58-6P 122860-66-6P

122860-68-8P 122882-85-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and reaction of, in preparation of muscarinic antagonists)


RN 122860-50-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-, 1-[imino(nitroamino)methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)




RN 122860-58-6 CAPLUS

CN Acetic acid, (5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)-, 1-[imino(nitroamino)methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)



RN 122860-66-6 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-, 1-[imino(nitroamino)methyl]-4-piperidinyl ester (9CI) (CA INDEX NAME)




RN 122860-68-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,




1,4,5,6-tetrahydro-2-(nitroamino)-5-pyrimidinyl ester (9CI) (CA INDEX NAME)



RN 122882-85-3 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-, 1-[imino(nitroamino)methyl]-3-piperidinyl ester (9CI) (CA INDEX NAME)



IT 122882-58-0P 122882-61-5P 122882-62-6P

122882-63-7P 122882-64-8P 122882-66-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as muscarinic antagonist)


RN 122882-58-0 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-acetic acid, 6,11-dihydro-6-oxo-, 1-(aminoiminomethyl)-4-piperidinyl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 122882-57-9

CMF C22 H24 N4 O3



CM 2


CRN 64-18-6

CMF C H2 O2

O=CH-OH

RN 122882-61-5 CAPLUS


CN Acetic acid, (5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)-, 1-(aminoiminomethyl)-4-piperidinyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122882-62-6 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-, 1-(aminoiminomethyl)-4-piperidinyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 122882-63-7 CAPLUS


CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,  
1-(aminoiminomethyl)-3-piperidinyl ester, monohydrochloride (9CI) (CA  
INDEX NAME)



● HCl

RN 122882-64-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,  
2-amino-1,4,5,6-tetrahydro-5-pyrimidinyl ester, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 122882-66-0 CAPLUS  
CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 6,11-dihydro-6-oxo-,  
[1-(aminoiminomethyl)-4-piperidinyl]methyl ester, monoformate (9CI) (CA  
INDEX NAME)


CM 1

CRN 122882-65-9  
CMF C22 H24 N4 O3




CM 2

CRN 64-18-6  
CMF C H2 O2



L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1987:4907 CAPLUS Full-text  
 DN 106:4907  
 TI Preparation of morphanthridine analogs as pharmaceuticals  
 IN Senda, Shigeo; Ueda, Takashi; Nakagawa, Kazuyuki  
 PA Otsuka Pharmaceutical Co., Ltd., Japan  
 SO Jpn. Kokai Tokkyo Koho, 21 pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 61167663	A2	19860729	JP 1985-7854	19850118
	JP 06065664	B4	19940824		
PRAI	JP 1985-7854		19850118		
GI					



I


AB Analogs of morphanthridine (I) are prepared and are useful in the treatment of arrhythmia, inflammation, diuresis, and ulcer. Thus, I was prepared by treating 5-methyl-11-carboxy-6-oxomorphanthridine first with thionyl chloride and then with diethylaminoethanol. Thirty-four I analogs were prepared. The inhibitory actions of I analogs on gastric acid secretion were demonstrated. No other pharmacol. studies were described.

IT **105671-18-9P 105671-33-8P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of, as pharmaceutical)


RN 105671-18-9 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 5-[2-(dimethylamino)-2-oxoethyl]-6,11-dihydro-6-oxo-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)





RN 105671-33-8 CAPLUS

CN 5H-Dibenz[b,e]azepine-11-carboxylic acid, 5-[2-(dimethylamino)-2-oxoethyl]-6,11-dihydro-6-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 1984:103199 CAPLUS Full-text  
 DN 100:103199  
 TI 5,6-Dihydro-11-alkylenemorphanthridin-6-ones and a drug containing them  
 IN Steiner, Gerd; Friedrich, Ludwig; Lenke, Dieter  
 PA BASF A.-G. , Fed. Rep. Ger.  
 SO Ger. Offen., 18 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3212794	A1	19831013	DE 1982-3212794	19820406
	CA 1215046	A1	19861209	CA 1983-424134	19830322
	EP 91057	A2	19831012	EP 1983-103054	19830328
	EP 91057	A3	19840502		
	EP 91057	B1	19860611		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AT 20345	E	19860615	AT 1983-103054	19830328
	JP 58192871	A2	19831110	JP 1983-58804	19830405
	US 4477451	A	19841016	US 1983-482004	19830405
PRAI	DE 1982-3212794	A	19820406		
	EP 1983-103054	A	19830328		
OS	CASREACT 100:103199				
GI					



AB Morphanthridinones I [R1,R2 = H, halo, C1-3 alkyl, CF3; R3 = C2-4 aminoalkyl, N (un)substituted with C1-3 alkyl or may complete a 5- to 7-membered saturated ring, optionally having N, O, or S atom as further heteroatom or CO group; R4 = H; R3R4 complete a 5- to 7-membered ring, C1-3 alkyl (un)substituted, optionally having CH2 or (CH2)2 bridge or a N atom alkyl (un)substituted or N-oxide], useful in treating gastric or duodenal ulcers (no data), were prepared. A mixture of cis- and trans-11-(carbomethoxymethylene)-5,6-dihydromorphanthridin-6-one was saponified with 10% aqueous alc. NaOH to give 94% of the free acids which were converted to 99% of the acid chlorides with SOCl2. Esterification of the acid chlorides with 4-(2-hydroxyethyl)morpholine gave 66% cis- and trans-II.


IT **88695-66-3**

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation as ulcer inhibitor)

RN 88695-66-3 CAPLUS

CN Acetic acid, (5,6-dihydro-6-oxo-11H-dibenz[b,e]azepin-11-ylidene)-,

8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester (9CI) (CA INDEX NAME)





=> d l1; d l2; d his; log y  
L1 HAS NO ANSWERS  
L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.

L2 HAS NO ANSWERS  
L2 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

Structure attributes must be viewed using STN Express query preparation.



(FILE 'STNGUIDE' ENTERED AT 18:52:38 ON 06 JAN 2005)  
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 18:59:17 ON 06 JAN 2005  
L1 STRUCTURE UPLOADED  
L2 STRUCTURE UPLOADED  
L3 1 S L1  
L4 4 S L2  
L5 4 S L1 OR L2  
L6 193 S L1 OR L2 FUL

FILE 'CAPLUS' ENTERED AT 19:02:50 ON 06 JAN 2005  
L7 6 S L6

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	30.09	280.76
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.38	-4.38

STN INTERNATIONAL LOGOFF AT 19:03:39 ON 06 JAN 2005



chain nodes :  
 16 17 19 20 21 22 24 25 26 28 29 49  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 30 31 32 33 34 35 36 37 38 39  
 ring/chain nodes :  
 23 27  
 chain bonds :  
 3-16 6-17 17-19 19-20 19-21 23-24 24-25 24-26 27-28 28-29  
 ring bonds :  
 1-2 1-7 1-11 2-3 3-4 4-5 4-12 5-6 5-15 6-7 7-8 8-9 9-10 10-11 12-13 13-14  
 14-15 30-31 30-34 31-32 32-33 33-34 35-36 35-39 36-37 37-38 38-39  
 exact/norm bonds :  
 1-2 2-3 3-4 3-16 5-6 6-7 6-17 17-19 19-20 19-21 23-24 24-25 24-26 27-28 28-29  
 30-31 30-34 31-32 32-33 33-34 35-36 35-39 36-37 37-38 38-39  
 normalized bonds :  
 1-7 1-11 4-5 4-12 5-15 7-8 8-9 9-10 10-11 12-13 13-14 14-15

S1:C,O

S2:[\*1],[\*2],[\*3],[\*4],[\*5]



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 19:CLASS 20:CLASS 21:CLASS  
 22:Atom 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:Atom  
 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 49:CLASS

Generic attributes :

22:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : less than 2  
 Type of Ring System : Monocyclic

Element Count :



chain nodes :  
 16 17 19 21 22 23 25 26 46 48 49 50 51  
 ring nodes :  
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 27 28 29 30 31 32 33 34 35 36  
 ring/chain nodes :  
 20 24  
 chain bonds :  
 3-16 6-17 17-48 20-21 21-22 21-23 24-25 25-26 48-49 49-50 49-51  
 ring bonds :  
 1-2 1-7 1-11 2-3 3-4 4-5 4-12 5-6 5-15 6-7 7-8 8-9 9-10 10-11 12-13 13-14  
 14-15 27-28 27-31 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36  
 exact/norm bonds :  
 1-2 2-3 3-4 3-16 5-6 6-7 6-17 17-48 20-21 21-22 21-23 24-25 25-26 27-28 27-31  
 28-29 29-30 30-31 32-33 32-36 33-34 34-35 35-36 48-49 49-50 49-51  
 normalized bonds :  
 1-7 1-11 4-5 4-12 5-15 7-8 8-9 9-10 10-11 12-13 13-14 14-15

1:C,O

2:[\*1],[\*2],[\*3],[\*4],[\*5]

match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
 12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:Atom 19:Atom 20:CLASS 21:CLASS  
 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom 28:Atom 29:Atom 30:Atom  
 31:Atom 32:Atom 33:Atom 34:Atom 35:Atom 36:Atom 46:CLASS 48:CLASS 49:CLASS  
 50:CLASS 51:CLASS

generic attributes :

19:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : less than 2  
 Type of Ring System : Monocyclic